Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

log into MY ENETS

ENETS Abstract Search

#1586 Biomarkers for Carcinoid Heart Disease

Introduction: Carcinoid heart disease (CHD) develops in patients with carcinoid syndrome. Currently NT-proBNP (NTP) is suggested as the best current biomarker to screen for CHD and monitor heart failure. A number of other markers have been investigated for heart failure.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Srirajaskanthan R

Authors: Basuroy R, Srirajaskanthan R, Ramage J, Sherwood R,

Keywords: carcinoid heart disease,

#1332 NT-proBNP is Superior to ST2 and Galectin-3 Cardiac Markers in Identifying Carcinoid Heart Disease in Small Bowel NET Patients

Introduction: Carcinoid heart disease (CHD) develops in small bowel neuroendocrine tumour (sbNET) patients with carcinoid syndrome (CS). NT-proBNP (NTP) is suggested as the best current biomarker to screen and monitor for HF from CHD. A number of other markers, such as Galectin-3 (GAL3) and ST2 (or IL-1 R4), have been explored to diagnose and prognosticate in HF but have not been explored in NET patients with CS and CHD.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Basuroy R, Srirajaskanthan R, Ramage J, Sherwood R,

Keywords: Carcinoid Heart Disease, Biomarker,

#1177 An Isolated Abnormal Chromogranin B Is Associated with Pancreato-Duodenal NETs and the Presence of Liver Metastases

Introduction: Chromogranin B (CgB) is a soluble secretory protein like chromogranin A (CgA) that has been reported to be elevated in patients with neuroendocrine tumours (NETs) but is not routinely assessed.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Basuroy R, Sherwood R, Srirajaskanthan R, Ramage J,

Keywords: chromogranin A, chromogranin B, pancreas, duodenal, assay, liver metastases,

#684 Clinical Characteristics and Survival of Neuroendocrine Tumors of Unknown Primary

Introduction: NETs of unknown primary account for 10-15% of NETs. There is limited published literature on this group of NETs.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Srirajaskanthan R

Authors: Srirajaskanthan R, Quaglia A, Vivian G, Mulholland N, Sherwood R,

Keywords: unknown primary, survival ,